| Company
| Aggregate Score
| P/E ratio
| Gross margin
| EBIT margin
| ROA
| Net income per employee
|
| Mersana Therapeutics, Inc.
|
| -0.67
| 99.1%
| -203.1%
| -111.8%
| -€596.15K
|
| Madrigal Pharmaceuticals, Inc.
|
| -22
| 95.3%
| -41.5%
| -21.2%
| -€475.13K
|
| Iovance Biotherapeutics, Inc.
|
| -1.9
| 38.8%
| -166.3%
| -43.9%
| -€411.72K
|
| ACADIA Pharmaceuticals Inc.
|
| 14
| 91.9%
| 23.0%
| 19.6%
| €347.04K
|
| Poseida Therapeutics, Inc.
|
| -15
| 95.4%
| -41.4%
| -20.2%
| -€147.26K
|
| Bellicum Pharmaceuticals, Inc.
|
| -0.035
| 100.0%
| -1,528.7%
| -318.1%
| -€1.45M
|
| Codiak BioSciences, Inc.
|
| 0
| 100.0%
| -158.8%
| -21.8%
| -€248.69K
|
| MannKind Corporation
|
| 40
| 75.2%
| 23.2%
| 5.9%
| €62.94K
|
| Veru Inc.
|
| -3
| 39.9%
| -512.6%
| -119.7%
| -€135.15K
|
| BridgeBio Pharma, Inc.
|
| -9.5
| 96.2%
| -172.2%
| -79.9%
| -€953.99K
|
| Medigene AG
|
| -0.12
| 78.4%
| -242.9%
| -57.8%
| -€191.39K
|
| Molecular Templates, Inc.
|
| -0.000042
| 63.3%
| -33.7%
| -58.5%
| -€218.68K
|
| Sino Biopharmaceutical Limited
|
| 164
| 81.8%
| 21.1%
| 5.2%
| €19.98K
|
| Futura Medical plc
|
| 0.22
| 68.7%
| 8.0%
| 9.5%
| €105.85K
|
| Aadi Bioscience, Inc.
|
| -6
| 89.2%
| -754.0%
| -9.4%
| -€338.79K
|
| Autolus Therapeutics plc
|
| -2.6
| -65.3%
| -535.8%
| -34.0%
| -€301.48K
|
| Arrowhead Pharmaceuticals, Inc.
|
| -15
| 35.4%
| -13.2%
| -10.9%
| -€215.14K
|
| Protalix BioTherapeutics, Inc.
|
| 23
| 57.5%
| 10.3%
| 6.6%
| €21.97K
|
| Atara Biotherapeutics, Inc.
|
| 2.6
| 81.6%
| 17.3%
| 77.6%
| €132.71K
|
| hVIVO plc
|
| 0.075
| 100.0%
| 20.5%
| 12.0%
| €56.00K
|
| MorphoSys AG
|
| -5.4
| 79.8%
| -219.7%
| -25.1%
| -€991.95K
|
| Axsome Therapeutics, Inc.
|
| -23
| 91.9%
| -37.8%
| -34.3%
| -€279.71K
|
| MacroGenics, Inc.
|
| -1.4
| 73.7%
| -90.1%
| -28.0%
| -€193.09K
|
| Incyte Corporation
|
| 11
| 92.9%
| 30.8%
| 18.8%
| €394.08K
|
| ORIC Pharmaceuticals, Inc.
|
| -4.9
| 41.8%
| -27,771.7%
| -31.4%
| -€962.06K
|
| Regeneron Pharmaceuticals, Inc.
|
| 12
| 84.4%
| 26.0%
| 11.4%
| €262.06K
|
| Applied Genetic Technologies Corporation
|
| 0
| 100.0%
| -15,888.3%
| -61.5%
| -€299.88K
|
| Innoviva, Inc.
|
| 10
| 84.8%
| -3.2%
| 8.9%
| €870.03K
|
| Seres Therapeutics, Inc.
|
| 13
| -4,005.7%
| -29,467.0%
| 3.8%
| €45.44K
|
| Vericel Corporation
|
| 169
| 73.8%
| 2.7%
| 2.9%
| €31.80K
|
| OptiBiotix Health Plc
|
| -0.69
| 36.5%
| -229.1%
| -2.1%
| -€21.89K
|
| Sutro Biopharma, Inc.
|
| -0.32
| 96.4%
| -175.7%
| -103.4%
| -€699.20K
|
| Seelos Therapeutics, Inc.
|
| 0.052
| 60.3%
| -1,480.0%
| 171.8%
| €443.71K
|
| Altimmune, Inc.
|
| -6.3
| -74,850.0%
| -452,310.0%
| -38.4%
| -€1.23M
|
| Jounce Therapeutics, Inc.
|
| -1.9
| 100.0%
| -63.7%
| -24.0%
| -€313.34K
|
| Capricor Therapeutics, Inc.
|
| -7.3
| -86.3%
| -778.8%
| -64.8%
| -€444.63K
|
| 4D pharma plc
|
| 0
| 100.0%
| -13,702.4%
| -28.3%
| -€130.10K
|
| Berkeley Lights, Inc.
|
| -0.86
| 69.4%
| -123.3%
| -33.3%
| -€304.55K
|
| G1 Therapeutics, Inc.
|
| -8.4
| 89.4%
| -65.1%
| -45.4%
| -€388.46K
|
| Editas Medicine, Inc.
|
| -0.84
| 97.0%
| -428.7%
| -99.1%
| -€704.85K
|
| Bio-Techne Corporation
|
| 103
| 65.5%
| 9.3%
| 3.1%
| €21.83K
|
| Paratek Pharmaceuticals, Inc.
|
| -1.9
| 84.9%
| -26.6%
| -46.0%
| -€217.31K
|
| CorMedix Inc.
|
| 6
| 92.6%
| 48.5%
| 21.6%
| €2.20M
|
| Viridian Therapeutics, Inc.
|
| -4.3
| 99.8%
| -463.5%
| -52.3%
| -€1.83M
|
| Nxera Pharma Co., Ltd.
|
| -26
| 72.5%
| -17.5%
| -2.3%
| -€45.96K
|
| Legend Biotech Corporation
|
| -14
| 59.9%
| -20.9%
| -14.0%
| -€80.14K
|
| Halozyme Therapeutics, Inc.
|
| 11
| 84.5%
| 59.3%
| 26.8%
| €1.48M
|
| ALK-Abelló A/S
|
| 42
| 65.0%
| 23.1%
| 12.1%
| €48.56K
|
| Equillium, Inc.
|
| -0.56
| 97.8%
| -554.9%
| -70.8%
| -€605.32K
|
| CytomX Therapeutics, Inc.
|
| 16
| 100.0%
| 20.5%
| 17.7%
| €204.29K
|
| Albireo Pharma, Inc.
|
| -6.6
| 95.6%
| -214.2%
| -42.8%
| -€916.94K
|
| Spero Therapeutics, Inc.
|
| -3.5
| 100.0%
| -155.6%
| -82.5%
| -€1.21M
|
| Emmaus Life Sciences, Inc.
|
| -0.15
| 92.2%
| -10.2%
| -35.1%
| -€186.02K
|
| ABIVAX SA
|
| -2.1
| 74.0%
| -9,534.8%
| -163.3%
| -€2.83M
|
| Oragenics, Inc.
|
| -0.34
| 0.0%
| -303.6%
| -481.4%
| -€2.98M
|
| Champions Oncology, Inc.
|
| 29
| 5.2%
| 8.8%
| 9.6%
| €12.08K
|
| Ocular Therapeutix, Inc.
|
| -5.6
| 88.9%
| -450.2%
| -60.8%
| -€790.64K
|
| Selecta Biosciences, Inc.
|
| -1.9
| 81.1%
| 122.8%
| -18.5%
| -€935.57K
|
| India Globalization Capital, Inc.
|
| -3.8
| 46.2%
| -731.8%
| -66.2%
| -€83.48K
|
| Stoke Therapeutics, Inc.
|
| 15
| 99.0%
| 13.2%
| 11.3%
| €274.99K
|
| BioMarin Pharmaceutical Inc.
|
| 32
| 81.3%
| 20.0%
| 4.4%
| €95.54K
|
| Catalyst Pharmaceuticals, Inc.
|
| 14
| 82.0%
| 44.8%
| 20.7%
| €1.04M
|
| Clinuvel Pharmaceuticals Limited
|
| 14
| 77.0%
| 46.2%
| 13.3%
| €1.35M
|
| Clovis Oncology, Inc.
|
| 0
| 65.6%
| -209.1%
| -72.6%
| -€529.23K
|
| Destiny Pharma plc
|
| -0.0051
| 99.3%
| -810.1%
| -56.8%
| -€432.23K
|
| Viracta Therapeutics, Inc.
|
| -0.017
| 55.4%
| -6,397.0%
| -197.1%
| -€1.44M
|
| Oxurion N.V.
|
| 0.19
| -4,050.0%
| -138,200.0%
| 39.3%
| €178.09K
|
| Genmab A/S
|
| 10
| 94.8%
| 36.5%
| 19.4%
| €447.37K
|
| OSE Immunotherapeutics SA
|
| 3.3
| 98.8%
| 38.0%
| 30.2%
| €585.08K
|
| Moderna, Inc.
|
| -4
| 11.7%
| -156.3%
| -25.7%
| -€466.15K
|
| Insmed Incorporated
|
| -15
| 69.7%
| -258.9%
| -50.1%
| -€808.18K
|
| Avid Bioservices, Inc.
|
| -5.2
| 7.7%
| -13.5%
| -47.0%
| -€355.61K
|
| XOMA Corporation
|
| 15
| 94.9%
| 4.8%
| 7.3%
| €1.29M
|
| ERYTECH Pharma S.A.
|
| -0.048
| 100.0%
| -3,787.7%
| -46.3%
| -€759.76K
|
| Novavax, Inc.
|
| 3.9
| 91.6%
| 30.5%
| 29.0%
| €311.48K
|
| Harpoon Therapeutics, Inc.
|
| -28
| 92.5%
| -104.8%
| -64.9%
| -€595.13K
|
| Northwest Biotherapeutics, Inc.
|
| -4.1
| 78.7%
| -6,927.3%
| -295.3%
| -€3.14M
|
| AVEO Pharmaceuticals, Inc.
|
| 0
| 87.4%
| -26.9%
| -40.0%
| -€308.42K
|
| Alterity Therapeutics Limited
|
| -8.4
| 97.7%
| -268.0%
| -26.4%
| -€724.34K
|
| Geron Corporation
|
| -12
| 86.2%
| -34.4%
| -14.1%
| -€303.08K
|
| Veracyte, Inc.
|
| 71
| 67.2%
| 5.0%
| 2.2%
| €31.92K
|
| Nanobiotix S.A.
|
| -3.9
| 100.0%
| -765.4%
| -114.3%
| -€478.18K
|
| Poxel S.A.
|
| -2.3
| 0.8%
| -434.8%
| -288.2%
| -€2.68M
|
| Genocea Biosciences, Inc.
|
| 0
| 100.0%
| -20,525.2%
| -101.2%
| -€460.40K
|
| Navidea Biopharmaceuticals, Inc.
|
| -0.059
| -19,972.8%
| -1,668,791.0%
| -20.7%
| -€93.27K
|
| Akebia Therapeutics, Inc.
|
| -58
| 78.8%
| 7.9%
| -4.4%
| -€76.25K
|
| Adaptive Biotechnologies Corporation
|
| -20
| 71.8%
| -30.9%
| -16.2%
| -€111.60K
|
| Oxford BioDynamics Plc
|
| -0.0056
| -713.5%
| -1,337.5%
| -94.7%
| -€282.99K
|
| Barinthus Biotherapeutics plc
|
| -0.64
| 159.2%
| 463.0%
| -55.2%
| -€498.42K
|
| Eiger BioPharmaceuticals, Inc.
|
| -0.17
| 95.9%
| -455.1%
| -193.1%
| -€1.16M
|
| Novo Nordisk A/S
|
| 22
| 82.0%
| 42.0%
| 20.3%
| €179.42K
|
| MedinCell S.A.
|
| -16
| 100.0%
| -147.9%
| -53.4%
| -€240.06K
|
| Oncopeptides AB (publ)
|
| -1.2
| 96.6%
| -512.4%
| -195.8%
| -€305.05K
|
| Genus plc
|
| 0.68
| 100.0%
| 6.3%
| 2.1%
| €6.32K
|
| Outlook Therapeutics, Inc.
|
| -1.7
| 70.8%
| -4,824.5%
| -194.0%
| -€1.64M
|
| Citius Pharmaceuticals, Inc.
|
| -0.25
| -26.5%
| -19,161.7%
| -32.0%
| -€1.54M
|
| Applied Therapeutics, Inc.
|
| -2.9
| 78.6%
| -9,850.2%
| -52.8%
| -€449.66K
|
| BioRestorative Therapies, Inc.
|
| -1.1
| 79.6%
| -3,785.1%
| -224.5%
| -€999.45K
|
| Crinetics Pharmaceuticals, Inc.
|
| -7.1
| -5,855.9%
| -31,130.2%
| -35.4%
| -€840.07K
|
| Marinus Pharmaceuticals, Inc.
|
| -0.21
| 88.9%
| -395.9%
| -220.8%
| -€738.79K
|
| Ardelyx, Inc.
|
| -16
| 89.5%
| -9.5%
| -11.6%
| -€124.21K
|
| Orgenesis Inc.
|
| -0.25
| 139.3%
| 724.9%
| -148.0%
| -€261.14K
|
| FibroGen, Inc.
|
| 0.14
| 82.7%
| 105.0%
| 157.4%
| €831.64K
|
| Pulmatrix, Inc.
|
| -4.8
| 100.0%
| -207,100.0%
| -124.8%
| -€2.70M
|
| Abivax S.A.
|
| -2.7
| 100.0%
| -3,487.3%
| -123.8%
| -€2.15M
|
| Liquidia Corporation
|
| -15
| 92.7%
| -155.0%
| -29.1%
| -€409.69K
|
| CTI BioPharma Corp.
|
| -15
| 94.1%
| -71.2%
| -68.6%
| -€526.16K
|
| BioCryst Pharmaceuticals, Inc.
|
| -251
| 97.4%
| 12.7%
| -2.0%
| -€13.13K
|
| TFF Pharmaceuticals, Inc.
|
| -0.015
| 76.9%
| -1,068.2%
| -261.7%
| -€845.84K
|
| Heidelberg Pharma AG
|
| -9.3
| 76.9%
| -640.2%
| -37.3%
| -€221.98K
|
| Bolt Biotherapeutics, Inc.
|
| -6.1
| 94.4%
| -884.4%
| -65.6%
| -€712.18K
|
| Novan, Inc.
|
| 2.6
| 65.8%
| -144.2%
| 1.3%
| €9.63K
|
| Pharma Mar, S.A.
|
| 35
| 95.0%
| 16.6%
| 12.1%
| €84.02K
|
| IGM Biosciences, Inc.
|
| -1.4
| 98.1%
| -19.2%
| -49.9%
| -€310.88K
|
| Mereo BioPharma Group plc
|
| -10
| 73.4%
| -9,398.2%
| -77.6%
| -€1.00M
|
| BioInvent International AB (publ)
|
| -7.8
| 98.6%
| -142.3%
| -41.2%
| -€250.75K
|
| Soligenix, Inc.
|
| -0.82
| -11.1%
| -183,452.1%
| -128.6%
| -€459.12K
|
| Sensorion SA
|
| -4.2
| 100.0%
| -775.6%
| -38.3%
| -€445.79K
|
| Ocugen, Inc.
|
| -5.2
| 100.0%
| -1,112.9%
| -111.2%
| -€584.72K
|
| Dianthus Therapeutics, Inc.
|
| -4.6
| 96.8%
| -4,558.4%
| -21.9%
| -€1.41M
|
| Vertex Pharmaceuticals Incorporated
|
| 31
| 86.3%
| 34.1%
| 14.8%
| €522.76K
|
| Zai Lab Limited
|
| -23
| 61.4%
| -51.6%
| -17.8%
| -€96.01K
|
| Zealand Pharma A/S
|
| 5.1
| 100.1%
| 78.8%
| 38.9%
| €2.32M
|
| Infinity Pharmaceuticals, Inc.
|
| -0.018
| 39.7%
| -1,636.7%
| -188.0%
| -€1.15M
|
| Camurus AB (publ)
|
| 47
| 93.2%
| 39.7%
| 16.9%
| €299.99K
|
| UCB SA
|
| 20
| 73.4%
| 24.4%
| 7.8%
| €147.15K
|
| Gritstone bio, Inc.
|
| -0.028
| -325.1%
| -8,786.8%
| -93.3%
| -€499.70K
|
| Takara Bio Inc.
|
| 165
| 58.3%
| 4.6%
| 0.4%
| €1.71K
|
| Gubra A/S
|
| 4.9
| 96.4%
| 83.5%
| 60.0%
| €898.97K
|
| Transgene SA
|
| -3.5
| 0.0%
| -40,410.2%
| -89.7%
| -€255.42K
|
| Matinas BioPharma Holdings, Inc.
|
| -0.3
| -12.9%
| -976.9%
| -180.3%
| -€5.06M
|
| GB Sciences, Inc.
|
| -0.15
| 100.0%
| -872.7%
| -1,104.5%
| -€452.65K
|
| Adverum Biotechnologies, Inc.
|
| -0.3
| 323.4%
| 4,419.3%
| -244.1%
| -€989.42K
|
| Agenus Inc.
|
| -4
| 20.2%
| -56.6%
| -15.1%
| -€96.71K
|
| Adagene Inc.
|
| -1.9
| -1,088.5%
| -41,197.5%
| -57.8%
| -€241.62K
|
| Krystal Biotech, Inc.
|
| 20
| 68.8%
| 42.4%
| 16.0%
| €627.60K
|
| Vanda Pharmaceuticals Inc.
|
| -3.2
| 0.3%
| -57.1%
| -14.0%
| -€198.53K
|
| EyePoint Pharmaceuticals, Inc.
|
| -2.9
| 94.1%
| -515.7%
| -81.7%
| -€1.08M
|
| Cardiff Oncology, Inc.
|
| -5.1
| 80.8%
| -10,719.6%
| -79.1%
| -€1.37M
|
| BRAIN Biotech AG
|
| -3.8
| 56.6%
| -16.4%
| -16.1%
| -€39.51K
|
| Aravive, Inc.
|
| -0.036
| -663.2%
| -372.7%
| -621.9%
| -€3.06M
|
| Alector, Inc.
|
| -1.5
| 92.3%
| -179.1%
| -32.1%
| -€534.17K
|
| Valneva SE
|
| -6.9
| 49.0%
| -25.6%
| -14.2%
| -€94.03K
|
| Quantum Genomics SA
|
| -1.6
| -24,586.5%
| -31,241.1%
| -84.6%
| -€1.06M
|
| Oxford Biomedica plc
|
| -0.095
| 43.9%
| -22.2%
| -17.1%
| -€49.98K
|
| Blueprint Medicines Corporation
|
| -53
| 95.8%
| -31.0%
| -13.0%
| -€198.13K
|
| Adocia SA
|
| -7.1
| -2.7%
| -5.3%
| -34.5%
| -€122.64K
|
| Lineage Cell Therapeutics, Inc.
|
| -2.3
| 97.8%
| -325.3%
| -75.5%
| -€838.64K
|
| Aligos Therapeutics, Inc.
|
| -0.54
| 64.9%
| -3,277.9%
| -78.8%
| -€1.07M
|
| Immutep Limited
|
| -6.2
| -1,117.5%
| -2,506.3%
| -39.1%
| -€1.93M
|
| Kura Oncology, Inc.
|
| -2.7
| 79.6%
| -230.5%
| -33.4%
| -€980.13K
|
| Sensei Biotherapeutics, Inc.
|
| -0.34
| 0.0%
| 527.8%
| -87.5%
| -€1.50M
|
| Clearside Biomedical, Inc.
|
| -2.4
| 85.6%
| -689.8%
| -223.3%
| -€704.88K
|
| Generex Biotechnology Corporation
|
| 0
| 48.2%
| -4,952.5%
| -8.6%
| -€227.39K
|
| KalVista Pharmaceuticals, Inc.
|
| -2.6
| 89.4%
| -1,646.0%
| -74.3%
| -€1.46M
|
| Syndax Pharmaceuticals, Inc.
|
| -3
| 96.2%
| -275.1%
| -56.5%
| -€1.00M
|
| Oxford Nanopore Technologies plc
|
| -0.11
| 57.0%
| -75.2%
| -16.0%
| -€89.10K
|
| WuXi Biologics (Cayman) Inc.
|
| 168
| 42.7%
| 29.3%
| 6.9%
| €41.98K
|
| Reata Pharmaceuticals, Inc.
|
| -81
| 96.5%
| -243.8%
| -15.9%
| -€216.40K
|
| Surface Oncology, Inc.
|
| -0.69
| 100.0%
| -298.0%
| -142.4%
| -€2.33M
|
| Catalyst Biosciences, Inc.
|
| 80
| 95.5%
| 11.2%
| 6.0%
| €14.22K
|
| Pharming Group N.V.
|
| 2.4K
| 89.9%
| 7.3%
| 0.1%
| €820.43
|
| Provectus Biopharmaceuticals, Inc.
|
| -4.9
| 20.2%
| -1,493.3%
| -1,595.7%
| -€968.95K
|
| Ultragenyx Pharmaceutical Inc.
|
| -6.1
| 83.3%
| -86.3%
| -48.7%
| -€388.80K
|
| Verastem, Inc.
|
| -1.3
| -247.6%
| -4,708.9%
| -136.3%
| -€2.68M
|
| Intellia Therapeutics, Inc.
|
| -1.9
| -41.7%
| -832.2%
| -48.2%
| -€959.84K
|
| Rhythm Pharmaceuticals, Inc.
|
| -21
| 89.4%
| -106.8%
| -37.9%
| -€589.67K
|
| PureTech Health plc
|
| 9.3
| 338.7%
| -2,001.2%
| 9.2%
| €549.65K
|
| Fate Therapeutics, Inc.
|
| -1.1
| 54.1%
| -2,448.2%
| -45.4%
| -€748.28K
|
| Sorrento Therapeutics, Inc.
|
| -0.0021
| 44.6%
| -720.9%
| -120.3%
| -€502.14K
|
| AnaptysBio, Inc.
|
| -8.2
| 81.1%
| -16.9%
| -24.0%
| -€539.94K
|
| Enanta Pharmaceuticals, Inc.
|
| -1.8
| 22.5%
| -149.4%
| -30.6%
| -€609.44K
|
| ImmunityBio, Inc.
|
| -8.1
| 89.8%
| -315.8%
| 0.0%
| -€450.80K
|
| Sage Therapeutics, Inc.
|
| -1.4
| 89.5%
| -461.3%
| -71.2%
| -€740.34K
|
| TG Therapeutics, Inc.
|
| 100
| 87.0%
| 18.9%
| 8.6%
| €149.03K
|
| Innate Pharma S.A.
|
| -3.4
| -170.4%
| -589.2%
| -49.6%
| -€254.43K
|
| GenSight Biologics S.A.
|
| -1.9
| 100.0%
| -602.4%
| -130.2%
| -€875.06K
|
| REGENXBIO Inc.
|
| -2.9
| 50.0%
| -96.0%
| -33.9%
| -€437.32K
|
| Ampio Pharmaceuticals, Inc.
|
| -0.00035
| 100.0%
| -3,884.9%
| -150.5%
| -€1.25M
|
| BioLineRx Ltd.
|
| -2.6
| 59.3%
| -84.1%
| -18.1%
| -€242.39K
|
| NRx Pharmaceuticals, Inc.
|
| -1.6
| 59.8%
| -5,704.5%
| -253.8%
| -€16.51M
|
| Hansa Biopharma AB (publ)
|
| -2.8
| 59.5%
| -302.2%
| -86.4%
| -€424.03K
|
| Bellerophon Therapeutics, Inc.
|
| -0.012
| 99.9%
| -195.7%
| -234.4%
| -€562.55K
|
| Arix Bioscience plc
|
| 0.12
| 37.5%
| 52.3%
| 6.2%
| €1.90M
|
| Revolution Medicines, Inc.
|
| -7.8
| 48.5%
| -396.4%
| -42.7%
| -€1.35M
|
| La Jolla Pharmaceutical Company
|
| 0
| 80.9%
| -5.5%
| 1.5%
| €21.64K
|
| Ionis Pharmaceuticals, Inc.
|
| -0.044
| 98.8%
| -28.8%
| -4,257.4%
| -€104.81M
|
| CymaBay Therapeutics, Inc.
|
| -33
| 97.8%
| -327.2%
| -25.7%
| -€959.40K
|
| Abcam plc
|
| 0
| 69.3%
| 3.8%
| 0.8%
| €4.26K
|
| Celyad Oncology SA
|
| -2.7
| -134.4%
| -3,596.8%
| -113.7%
| -€381.12K
|
| Avacta Group Plc
|
| -0.053
| 33.4%
| -136.5%
| -29.0%
| -€192.66K
|
| Addex Therapeutics Ltd
|
| -1.6
| 100.0%
| -2,624.3%
| -71.1%
| -€3.28M
|
| Ocuphire Pharma, Inc.
|
| -0.83
| 608.8%
| 1,501.0%
| -196.4%
| -€4.40M
|
| Atreca, Inc.
|
| -0.037
| -2,420.2%
| -22,844.5%
| -360.9%
| -€916.63K
|
| Concert Pharmaceuticals, Inc.
|
| 0
| 100.0%
| -121,474.9%
| -38.8%
| -€900.95K
|
| Genfit S.A.
|
| -4.8
| 81.6%
| -72.1%
| -17.9%
| -€215.33K
|
| AnGes, Inc.
|
| -0.89
| 36.6%
| -900.5%
| -494.2%
| -€2.83M
|
| ChromaDex Corporation
|
| 54
| 133.7%
| 32.4%
| 20.8%
| €170.44K
|
| Karyopharm Therapeutics Inc.
|
| -0.3
| 95.9%
| -73.1%
| -129.5%
| -€387.57K
|
| Laboratorios Farmaceuticos Rovi, S.A.
|
| 14
| 65.2%
| 26.8%
| 23.2%
| €91.68K
|
| Adaptimmune Therapeutics plc
|
| -0.41
| 94.8%
| -252.3%
| -129.9%
| -€291.09K
|
| Kuros Biosciences AG
|
| -175
| 88.5%
| 3.9%
| -5.5%
| -€54.20K
|
| Heron Therapeutics, Inc.
|
| -23
| 73.9%
| 1.0%
| -5.5%
| -€96.57K
|
| BioSenic S.A.
|
| -0.18
| 90.7%
| -125.6%
| -79.2%
| -€372.00K
|
| KemPharm, Inc.
|
| -31
| 73.8%
| -153.2%
| -6.0%
| -€585.09K
|
| Onconova Therapeutics, Inc.
|
| -0.000000062
| -51,242.7%
| -62,233.8%
| -1,338,153.0%
| -€9.03T
|
| Armata Pharmaceuticals, Inc.
|
| -1.6
| 75.5%
| -730.9%
| -52.4%
| -€678.25K
|
| Sangamo Therapeutics, Inc.
|
| -1.1
| 100.0%
| -331.6%
| -122.9%
| -€516.38K
|
| X4 Pharmaceuticals, Inc.
|
| -0.19
| 83.2%
| -291.1%
| -58.1%
| -€577.01K
|
| AgeX Therapeutics, Inc.
|
| -7
| -50.6%
| -33,703.8%
| -70.0%
| -€1.89M
|
| Cytokinetics, Incorporated
|
| -5.2
| -127.5%
| -656.9%
| -52.3%
| -€1.31M
|
| Immunocore Holdings plc
|
| -63
| 99.3%
| -11.9%
| -2.6%
| -€49.74K
|
| Omeros Corporation
|
| -1.7
| -48.5%
| -31,401.7%
| -65.2%
| -€520.43K
|
| Deinove SA
|
| -0.15
| -4,300.0%
| -7,389.2%
| -70.8%
| -€167.06K
|
| Precision BioSciences, Inc.
|
| -0.66
| -1.6%
| -12,980.9%
| -89.4%
| -€671.66K
|
| Idorsia Ltd
|
| -3.3
| 65.7%
| -48.5%
| -26.8%
| -€227.43K
|
| Silence Therapeutics plc
|
| -0.24
| 35.0%
| -379.8%
| -10.7%
| -€175.07K
|
| Larimar Therapeutics, Inc.
|
| -1.5
| 63.9%
| -57,996.7%
| -70.5%
| -€1.76M
|
| IXICO plc
|
| -0.074
| 49.0%
| -31.4%
| -11.0%
| -€21.87K
|
| ImmunoGen, Inc.
|
| -118
| 98.7%
| -27.9%
| -8.9%
| -€228.90K
|
| argenx SE
|
| 33
| 88.9%
| 18.0%
| 15.1%
| €586.53K
|
| PhaseBio Pharmaceuticals, Inc.
|
| 0
| 100.0%
| 3,588.2%
| 125.6%
| €402.54K
|
| Acer Therapeutics Inc.
|
| 0
| 77.5%
| -7,376.2%
| -346.3%
| -€1.40M
|
| Polyphor AG
|
| 0
| 100.0%
| -637,861.2%
| -28.5%
| -€681.53K
|
| Oramed Pharmaceuticals Inc.
|
| -3.7
| -2.4%
| -683.7%
| -14.9%
| -€1.61M
|
| Cara Therapeutics, Inc.
|
| -12
| 61.0%
| -308.2%
| -47.8%
| -€1.81M
|
| Starpharma Holdings Limited
|
| -7.1
| -72.3%
| -408.1%
| -30.3%
| -€114.65K
|
| ReNeuron Group plc
|
| -0.000092
| -6.0%
| -2,466.3%
| -79.0%
| -€223.62K
|
| Amicus Therapeutics, Inc.
|
| 94
| 90.5%
| 4.5%
| 2.3%
| €34.56K
|
| Rigel Pharmaceuticals, Inc.
|
| 3.3
| 93.1%
| 42.2%
| 46.7%
| €606.84K
|
| Pieris Pharmaceuticals, Inc.
|
| -0.51
| -1,260.4%
| -23,801.9%
| -52.4%
| -€661.44K
|
| Alpine Immune Sciences, Inc.
|
| -120
| 59.5%
| -90.9%
| -9.9%
| -€225.08K
|
| Mirati Therapeutics, Inc.
|
| -5.6
| -283.5%
| -2,002.7%
| -64.3%
| -€1.07M
|
| BB Biotech AG
|
| -4
| 99.3%
| 115.0%
| -23.8%
| -€47.62M
|
| Verrica Pharmaceuticals Inc.
|
| -2.1
| 91.9%
| -53.2%
| -63.6%
| -€317.91K
|
| Ascendis Pharma A/S
|
| -33
| 86.8%
| -22.5%
| -20.2%
| -€229.05K
|
| Chimerix, Inc.
|
| -9
| 100.0%
| -45,550.5%
| -60.5%
| -€970.78K
|
| Coherus BioSciences, Inc.
|
| 0.6
| 45.3%
| -212.4%
| 30.0%
| €589.76K
|
| scPharmaceuticals Inc.
|
| -2.3
| 68.5%
| -133.2%
| -114.3%
| -€491.23K
|
| NGM Biopharmaceuticals, Inc.
|
| -0.91
| 26.3%
| -3,429.1%
| -82.8%
| -€879.17K
|
| Carisma Therapeutics, Inc.
|
| 3.1
| 86.1%
| 146.9%
| 122.7%
| €151.69K
|
| Verona Pharma plc
|
| -94
| 95.2%
| -25.3%
| -14.2%
| -€337.05K
|
| Amarin Corporation plc
|
| -63
| 44.2%
| -45.5%
| -13.1%
| -€271.95K
|
| Nicox S.A.
|
| -0.87
| 24.6%
| 124.0%
| -25.7%
| -€567.03K
|
| Centessa Pharmaceuticals plc
|
| -6.8
| 97.4%
| -1,425.3%
| -54.1%
| -€2.73M
|
| Homology Medicines, Inc.
|
| -0.79
| -0.4%
| 2,808.2%
| -44.9%
| -€3.21M
|
| Genprex, Inc.
|
| -0.49
| 0.0%
| -134,539.7%
| -451.6%
| -€999.91K
|
| Inventiva S.A.
|
| -1.3
| 86.4%
| -621.0%
| -174.2%
| -€2.73M
|
| Alnylam Pharmaceuticals, Inc.
|
| 886
| 84.0%
| 8.2%
| 0.9%
| €16.95K
|
| Cartesian Therapeutics, Inc.
|
| -5.6
| -1,073.0%
| -8,386.5%
| -12.9%
| -€630.76K
|
| Santhera Pharmaceuticals Holding AG
|
| -2.5
| 12.0%
| -104.1%
| -50.1%
| -€912.08K
|
| Marker Therapeutics, Inc.
|
| -1.4
| -54.9%
| -280.8%
| -98.9%
| -€2.53M
|
| Savara Inc.
|
| -3.3
| 22.8%
| -44,597.1%
| -82.1%
| -€1.70M
|
| Codexis, Inc.
|
| -3
| 79.3%
| -112.7%
| -51.6%
| -€295.15K
|
| BioNTech SE
|
| -39
| 82.5%
| -29.6%
| -2.7%
| -€84.41K
|
| Provention Bio, Inc.
|
| -21
| 96.0%
| -993.9%
| -47.7%
| -€563.36K
|
| ObsEva SA
|
| 1.8
| 54.1%
| 3.4%
| 87.8%
| €458.25K
|
| Nektar Therapeutics
|
| -0.97
| 86.9%
| -156.7%
| -40.1%
| -€1.72M
|
| IDEAYA Biosciences, Inc.
|
| -12
| 3.0%
| -97.2%
| -13.5%
| -€1.06M
|
| United Therapeutics Corporation
|
| 9.7
| 88.6%
| 47.7%
| 17.3%
| €845.54K
|
| Spectrum Pharmaceuticals, Inc.
|
| -3.2
| 88.7%
| -246.4%
| -60.4%
| -€656.37K
|
| Ovid Therapeutics Inc.
|
| -0.62
| 98.2%
| -618.3%
| -56.9%
| -€1.37M
|
| Fortress Biotech, Inc.
|
| 15
| 71.6%
| -143.6%
| 2.2%
| €34.25K
|
| IntelGenx Technologies Corp.
|
| -2.7
| -83.1%
| -998.7%
| -168.4%
| -€199.39K
|
| BioXcel Therapeutics, Inc.
|
| -0.16
| -46.3%
| -7,106.6%
| -152.3%
| -€1.60M
|
| Roquefort Therapeutics plc
|
| -0.024
| -692.2%
| -41,336.8%
| -16.9%
| -€159.11K
|
| Corcept Therapeutics Incorporated
|
| 71
| 98.2%
| 8.8%
| 12.8%
| €182.53K
|
| Scorpius Holdings, Inc.
|
| -0.000000039
| 35.3%
| -634.8%
| -265.5%
| -€603.73B
|
| Sarepta Therapeutics, Inc.
|
| -14
| 21.4%
| -5.2%
| -7.8%
| -€171.71K
|
| PTC Therapeutics, Inc.
|
| 5.3
| 90.8%
| 43.6%
| 28.4%
| €694.63K
|
| Basilea Pharmaceutica AG
|
| 10
| 48.2%
| 34.7%
| 26.0%
| €428.59K
|
| Agios Pharmaceuticals, Inc.
|
| -5
| 84.4%
| -1,061.8%
| -29.0%
| -€716.40K
|
| Plus Therapeutics, Inc.
|
| -0.52
| 89.1%
| -366.4%
| -110.2%
| -€850.16K
|
| Cellectis S.A.
|
| -3.5
| 91.0%
| -35.1%
| -10.3%
| -€142.01K
|
| Precigen, Inc.
|
| -1.8
| 25.3%
| -1,798.2%
| -144.1%
| -€1.50M
|
| BeiGene, Ltd.
|
| 377
| 86.2%
| 3.7%
| 0.9%
| €5.41K
|
| E-therapeutics Plc
|
| -0.051
| 14.8%
| -4,337.7%
| -44.7%
| -€376.39K
|
| Humanigen, Inc.
|
| 0
| 100.0%
| -3,061.2%
| -1,041.9%
| -€7.71M
|
| Immuron Limited
|
| -2.5
| 65.1%
| -75.5%
| -65.0%
| -€560.45K
|
